Transfusion Medicine Institute

Shenyang, China

Transfusion Medicine Institute

Shenyang, China

Time filter

Source Type

Zhou Y.,Panjin Blood Bank | Li J.-P.,Transfusion Medicine Institute | Li J.-P.,Key Laboratory of Blood Safety Research of Liaoning Province | Li J.-P.,Key Laboratory of Blood Safety Research of Shenyang | Li J.-P.,Shenyang Research Center for Stem Cell Clinical Application
Chinese Journal of Tissue Engineering Research | Year: 2015

BACKGROUND: In recent years, with the development of China Marrow Donor Program and the improvement of human leukocyte antigen (HLA) typing technique, novel alleles of human leukocyte antigen have been discovered constantly in China. OBJECTIVE: To identify and confirm a novel HLA allele in a Chinese individual. METHODS: A new HLA allele was found during routine human leukocyte antigen genotyping by PCR-sequence specific oligonucleotide probes and sequencing-based typing. RESULTS AND CONCLUSION: The HLA-B locus hybridization probe reaction patterns of this sample did not match with any known HLA-B alleles or allelic combinations. Exons 2, 3 were sequenced in both directions using HLA-B sequence primer and group-specific sequencing primer. The obtained sequence had 2nts change from B*07:02:01 at nt 226 and nt 228 where A->G (codon 76 ATA->GTG) and resulting in a coding change, 76 isoleucine (I) was changed to valine (V). This nucleotide sequence has been submitted to the GenBank nucleotide sequence database and it is available under the accession number HM989017. A novel HLA allele, HLA-B*07:110, was identified, and was named officially by the WHO Nomenclature Committee. © 2015, Journal of Clinical Rehabilitative Tissue Engineering Research. All Rights Reserved.


Yin H.,Liaoning Medical University | Li X.F.,Transfusion Medicine Institute | Li X.F.,Key Laboratory of Blood Safety Research of Liaoning | Li X.F.,Key Laboratory of Blood Safety Research of Shenyang | And 4 more authors.
Chinese Journal of Tissue Engineering Research | Year: 2015

BACKGROUND: In recent years, with the development of China Marrow Donor Program and the improvement of human leukocyte antigen (HLA) typing technique, novel HLA alleles have been discovered constantly in China. OBJECTIVE: To identify and confirm a novel HLA allele in a Chinese individual. METHODS: A new HLA allele was found in a 27-year-old male Han volunteer donor of hematopoietic stem cells during routine HLA genotyping by PCR-sequence specific oligonucleotide probes and sequencing-based typing. RESULTS AND CONCLUSION: The HLA-B locus hybridization probe reaction patterns of this sample did not match to any known HLA-B alleles or allelic combinations. Exons 2-3 were sequenced in both directions using HLA-B sequence primer and group-specific sequencing primer. The new sequence had 1 nt change from its closest allele B*55:02:01 at nucleotide 412 where A→G (codon138 AAC→GAC) resulting in a coding change, 138 Asparagine (N) was changed to Aspartate (D). The nucleotide sequence has been submitted to the GenBank nucleotide sequence database and it is available under the accession number HM989018. A novel HLA allele, HLA-B*55:46, has been identified, and named officially by the WHO Nomenclature Committee.


Xu J.-H.,First Peoples Hospital Of Shenyang | Li X.-F.,Transfusion Medicine Institute | Li X.-F.,Key Laboratory of Blood Safety Research of Liaoning | Li X.-F.,Key Laboratory of Blood Safety Research of Shenyang
Chinese Journal of Tissue Engineering Research | Year: 2015

BACKGROUND: Hematopoietic stem cell transplantation is an important means for clinical cure of hematologic malignancies, congenital hereditary diseases and autoimmune diseases. Although ABO-incompatibility has no effects on the survival of transplanted hematopoietic stem cells, the transfusion strategy to ABO-incompatible grafts in allogeneic hematopoietic stem cell transplantation is worth studying. OBJECTIVE: To explore the antigen-antibody changes during blood conversion after ABO-incompatible hematopoietic stem cell transplantation as well as transfusion strategies. METHODS: Blood grouping, antibody detection, antibody titer determination, cross-match test were employed for antigen-antibody monitoring during blood conversion and pre-transfusion compatibility detection in 24 cases undergoing ABO-incompatible allogeneic hematopoietic stem cell transplantation. Another 30 cases undergoing ABO-compatible allogeneic hematopoietic stem cell transplantation were enrolled as controls to select the appropriate blood. RESULTS AND CONCLUSION: All of the 24 ABO-incompatible patients developed the hematopoietic reconstitution after transplantation, but both major and major-minor ABO incompatibility were different from ABO compatibility in the time of erythrocytic recovery (P < 0.05). According to the changes of ABO antigen and antibody during the blood conversion, the patients of major ABO incompatibility were selected the red blood cells of their own type, the patients of minor ABO incompatibility were selected the red blood cells of the blood group from patients to donors gradually, and the patients of major-minor ABO incompatibility were selected the red blood cells from O-type blood to donor’s type gradually. None of the 24 recipients presented hemolytic reaction during transplantation and after transfusion. Therefore, the transfusion strategy to ABO-incompatible grafts in allogeneic hematopoietic stem cell transplantation is dynamically varied according to the changes of patient’s ABO antigen and antibody, and evaluating the recovery of erythropoietic system can guide blood component selection, avoid hemolytic transfusion reaction, and insure the safety of hematopoietic stem cell transplantation. © 2015 Journal of Clinical Rehabilitative Tissue Engineering Research. All rights reserved.

Loading Transfusion Medicine Institute collaborators
Loading Transfusion Medicine Institute collaborators